New Zealand's BLIS Technologies Q1 revenue rises on ingredient sales growth

BLIS Technologies

19/08/2026 21:44

Overview
New Zealand probiotic maker's Q1 revenue rose 42% yr/yr to NZ$5.1 mln
Q1 EBITDA swung to NZ$1.1 mln profit from NZ$0.2 mln loss last year
Company expects FY27 revenue growth of 10%-15%

Outlook
BLIS Technologies forecasts FY27 revenue growth of 10%-15%

Result Drivers
B2B SEGMENT GROWTH - Co said B2B revenue rose 67% yr/yr, driven by ingredient sales in Asia Pacific, Probi royalties, and private label sales into China
EUROPE WEAKNESS - Ingredient revenue in Europe was weaker, partially offsetting B2B gains
B2C MODEST GROWTH - Total B2C revenue was up 4% yr/yr

Company press release: ID:nNZS87ga

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
 
NZ$5.10 mln
 
Q1 EBITDA
 
NZ$1.10 mln
 

Reuters Recommended Reads
Aug 17 - New Zealand's a2 Milk tumbles on weak earnings forecast, profit miss
Aug 19 - NZ's Fletcher Building warns on first-half earnings, swings to annual profit
Aug 17 - Vaccine maker Sinovac H1 revenue rises on overseas growth, approvals

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)